Ponatinib Versus Imatinib in Patients with Newly Diagnosed Ph plus ALL: Subgroup Analysis of the Phase 3 Phallcon Study

被引：0

作者：

Aldoss, Ibrahim ^{[1
]}

Ribera, Josep-Maria ^{[2
]}

Kantarjian, Hagop ^{[3
]}

Montesinos, Pau ^{[4
]}

Leonard, Jessica T. ^{[5
]}

Gomez-Almaguer, David ^{[6
]}

Baer, Maria R. ^{[7
]}

Gambacorti-Passerini, Carlo ^{[8
]}

McCloskey, James ^{[9
]}

Minami, Yosuke ^{[10
]}

Papayannidis, Cristina ^{[11
]}

Rocha, Vanderson ^{[12
]}

Rousselot, Philippe ^{[13
]}

Vachhani, Pankit ^{[14
]}

Wang, Eunice S. ^{[15
]}

Hennessy, Meliessa ^{[16
]}

Patel, Niti ^{[16
]}

Vorog, Alexander ^{[16
]}

Wang, Bingxia ^{[16
]}

Jabbour, Elias ^{[17
]}

机构：

[1] City Hope Natl Med Ctr, Duarte, CA USA

[2] Hosp Badalona Germans Trias & Pujol, ICO Badalona, Josep Carreras Leukaemia Res Inst, Badalona, Spain

[3] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX USA

[4] Hosp Univ & Politecn La Fe Valencia, Valencia, Spain

[5] Oregon Hlth & Sci Univ, Portland, OR USA

[6] UANL, Hosp Univ Dr Jose Eleuterio Gonzalez, Monterrey, Mexico

[7] Univ Maryland, Dept Med, Sch Med, Baltimore, MD USA

[8] Univ Milano Bicocca, Monza, Italy

[9] Hackensack Univ, Med Ctr, Hackensack, NJ USA

[10] Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan

[11] IRCCS Azienda Osped Univ Bologna, Ist Ematol Seragnoli, Bologna, Italy

[12] Univ Sao Paulo, Inst Canc Estado Sao Paulo, Sao Paulo, Brazil

[13] Univ Versailles Paris Saclay, Ctr Hosp Verailles, UMR1184, Versailles, France

[14] Univ Alabama Birmingham, Birmingham, AL USA

[15] Roswell Pk Comprehens Canc Ctr, Buffalo, NY USA

[16] Takeda Dev Ctr Amer Inc, Lexington, MA USA

[17] Univ Texas MD Anderson Canc Ctr, Houston, TX USA

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-179537

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：5

共 50 条

[21] A COST-CONSEQUENCE ANALYSIS OF PONATINIB VERSUS IMATINIB IN PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA IN THE UNITED STATES
Hernandez, L. G.
Davies, S.
Li, C.
Reddick, L. E.
Jensen, I
VALUE IN HEALTH, 2024, 27 (06) : S88 - S88
[22] An Ongoing Phase 3 Study of Bosutinib (SKI-606) Versus Imatinib In Patients with Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia
Gambacorti-Passerini, Carlo
Kim, Dong-Wook
Kantarjian, Hagop M.
Brummendorf, Tim H.
Dyagil, Irina
Griskevicius, Laimonas
Malhotra, Hemant
Goh, Yeow-Tee
Wang, Junyuan
Gogat, Karin
Cortes, Jorge
BLOOD, 2010, 116 (21) : 95 - 96
[23] Oral arsenic plus imatinib versus imatinib solely for newly diagnosed chronic myeloid leukemia: a randomized phase 3 trial with 5-year outcomes
Tian, Jie
Song, Yong-Ping
Zhang, Gao-Chong
Wang, Shu-Fang
Chu, Xiao-Xiang
Chai, Ye
Wang, Chun-Ling
He, Ai-Li
Zhang, Feng
Shen, Xu-Liang
Zhang, Wei-Hua
Yang, Lin-Hua
Nie, Da-Nian
Wang, Dong-Mei
Zhu, Huan-Ling
Gao, Da
Lou, Shi-Feng
Zhou, Ze-Ping
Su, Guo-Hong
Li, Yan
Lin, Jin-Ying
Shi, Qing-Zhi
Ouyang, Gui-Fang
Jing, Hong-Mei
Chen, Sai-Juan
Li, Jian
Mi, Jian-Qing
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2024, 150 (04)
[24] A prospective, randomized study to compare the combination of imatinib and cytarabine versus imatinib alone in newly diagnosed patients with chronic phase chronic myeloid leukemia
Samal, Priyanka
Chakrabarti, Prantar
Nath, Uttam K.
INDIAN JOURNAL OF CANCER, 2019, 56 (03) : 211 - 215
[25] A Phase I/II study of nilotinib in Japanese patients with imatinib-resistant or -intolerant Ph plus CML or relapsed/refractory Ph plus ALL
Tojo, Arinobu
Usuki, Kensuke
Urabe, Akio
Maeda, Yasuhiro
Kobayashi, Yukio
Jinnai, Itsuro
Ohyashiki, Kazuma
Nishimura, Miki
Kawaguchi, Tatsuya
Tanaka, Hideo
Miyamura, Koichi
Miyazaki, Yasushi
Hughes, Timothy
Branford, Susan
Okamoto, Shinichiro
Ishikawa, Jun
Okada, Masaya
Usui, Noriko
Tanii, Hiromi
Amagasaki, Taro
Natori, Hiroko
Naoe, Tomoki
INTERNATIONAL JOURNAL OF HEMATOLOGY, 2009, 89 (05) : 679 - 688
[26] Nilotinib as frontline therapy for patients with newly diagnosed Ph plus chronic myeloid leukemia in chronic phase: results from the Japanese subgroup of ENESTnd
Nakamae, Hirohisa
Shibayama, Hirohiko
Kurokawa, Mineo
Fukuda, Tetsuya
Nakaseko, Chiaki
Kanda, Yoshinobu
Nagai, Tadashi
Ohnishi, Kazunori
Maeda, Yasuhiro
Matsuda, Akira
Amagasaki, Taro
Yanada, Masamitsu
INTERNATIONAL JOURNAL OF HEMATOLOGY, 2011, 93 (05) : 624 - 632
[27] Long-term data from a phase 3 study of radotinib versus imatinib in patients with newly diagnosed, chronic myeloid leukaemia in the chronic phase (RERISE)
Do, Young Rok
Kwak, Jae-Yong
Kim, Jeong A.
Kim, Hyeoung Joon
Chung, Joo Seop
Shin, Ho-Jin
Kim, Sung-Hyun
Bunworasate, Udomsak
Choi, Chul Won
Zang, Dae Young
Oh, Suk Joong
Jootar, Saengsuree
Reksodiputro, Ary Harryanto
Lee, Won Sik
Mun, Yeung-Chul
Kong, Jee Hyun
Caguioa, Priscilla B.
Kim, Hawk
Park, Jinny
Kim, Dong-Wook
BRITISH JOURNAL OF HAEMATOLOGY, 2020, 189 (02) : 303 - 312
[28] Phase 3 study of nilotinib vs imatinib in Chinese patients with newly diagnosed chronic myeloid leukemia in chronic phase: ENESTchina
Wang, Jianxiang
Shen, Zhi-Xiang
Saglio, Giuseppe
Jin, Jie
Huang, He
Hu, Yu
Du, Xin
Li, Jianyong
Meng, Fanyi
Zhu, Huanling
Hu, Jianda
Wang, Jianmin
Hou, Ming
Hertle, Sabine
Menssen, Hans D.
Ortmann, Christine-Elke
Tribouley, Catherine
Yuan, Ye
Baccarani, Michele
Huang, Xiaojun
BLOOD, 2015, 125 (18) : 2771 - 2778
[29] Subgroup analysis of DIA-AID 1, an immune intervention phase 3 study in newly diagnosed type 1 diabetes patients
Pozzilli, P.
Raz, I.
Linn, T.
Bonnici, F.
Elias, D.
Avron, A.
Tamir, M.
Eren, R.
Dagan, S.
DIABETOLOGIA, 2013, 56 : S230 - S230
[30] Efficacy and Toxicity of Frontline Ponatinib Plus Blinatumomab for Adult Ph plus ALL Patients of All Ages. Intermediate Analysis of the Gimema ALL2820
Chiaretti, Sabina
Leoncin, Matteo
Elia, Loredana
Soddu, Stefano
Piciocchi, Alfonso
Matarazzo, Mabel
Di Trani, Mariangela
Martelli, Maurizio
Borlenghi, Erika
Parisi, Marina
Mancini, Valentina
Alati, Caterina
Mattei, Daniele G.
Martelli, Maria Paola
Salutari, Prassede
Chiusolo, Patrizia
Audisio, Ernesta
Luppi, Mario
Pochintesta, Lara
Pasciolla, Crescenza
Serio, Bianca
Scappini, Barbara
Cucca, Antonella
Chiarucci, Martina
Bonifacio, Massimiliano
Fracchiolla, Nicola
Imbergamo, Silvia
Ammirati, Lucia
Mosna, Federico
Zappasodi, Patrizia
Mastaglio, Sara
Pietrasanta, Daniela
Bocchia, Monica
Lunghi, Monia
Todisco, Elisabetta
Fazi, Paola
Rambaldi, Alessandro
Foa, Robin
BLOOD, 2024, 144 : 835 - 837

← 1 2 3 4 5 →